The program will provide an overview of CCM therapy, a breakthrough technology that is FDA approved and indicated for NYHA Stage III Patients with an EF 25-45% on GMDT, in normal sinus rhythm, are NOT indicated for CRT, but remain symptomatic. The Optimizer® device was designed to increase the contractility of the heart. Faculty will discuss cardiac contractility modulation mechanism of action, summarize the clinical trials leading to the FDA-approved therapy, and provide an overview of the implant procedure as well as mechanism for patient identification and screening.

Healthcare professionals who manage the care of heart failure patients.

Joyce Wald, DO

Nirav Ravai, MD

Rami Kahwash, MD

Emad Aziz, DO

The content in this Industry Theatre represents the beliefs of the speakers and do not necessarily represent the views of Impulse Dynamics USA, Inc. or HFSA.

"Hope is Here - A Modern Approach for Heart Failure Treatment" are not sponsored or endorsed by the HFSA.

The Industry Theatre is not offered in the HFSA-accredited continuing education catalog; therefore, it is ineligible for continuing education units. No committee members or representatives of the HFSA have been involved in the planning of this activity.